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Abstract
Background: Large-artery intracranial atherosclerosis may be the most frequent cause of ischemic stroke
worldwide. Traditional approaches have attempted to target the disease when it is already symptomatic. However,
early detection of intracranial atherosclerosis may allow therapeutic intervention while the disease is still
asymptomatic. The prevalence and natural history of asymptomatic intracranial atherosclerosis in Caucasians remain
unclear. The aims of the Barcelona-ASymptomatic Intracranial Atherosclerosis (ASIA) study are (1) to determine the
prevalence of ASIA in a moderate-high vascular risk population, (2) to study its prognostic impact on the risk of
suffering future major ischemic events, and (3) to identify predictors of the development, progression and clinical
expression of this condition.
Methods/Design: Cross-over and cohort, population-based study. A randomly selected representative sample of
1,503 subjects with a mild-moderate-high vascular risk (as defined by a REGICOR score ≥ 5%) and with neither a
history of cerebrovascular nor ischemic heart disease will be studied. At baseline, all individuals will undergo
extracranial and transcranial Color-Coded Duplex (TCCD) ultrasound examinations to detect presence and severity
of extra and intracranial atherosclerosis. Intracranial stenoses will be assessed by magnetic resonance angiography
(MRA). Clinical and demographic variables will be recorded and blood samples will be drawn to investigate clinical,
biological and genetic factors associated with the presence of ASIA. A long-term clinical and sonographic follow-
up will be conducted thereafter to identify predictors of disease progression and of incident vascular events.
Discussion: The Barcelona-ASIA is a population-based study aiming to evaluate the prevalence and clinical
importance of asymptomatic intracranial large-artery atherosclerosis in Caucasians. The ASIA project may provide a
unique scientific resource to better understand the dynamics of intracranial atherosclerosis from its early stages
and to identify new potential therapeutic targets for this condition.
Background
Atherosclerosis is a systemic disease with multifactorial
etiology now considered the primary cause of morbidity
and mortality in developing countries.
Large artery intracranial atherosclerosis disease
(ICAD) is a major public health problem as it is prob-
ably the major cause of stroke worldwide and conse-
quently, a main cause of long-term disability and
mortality [1]. Accumulating evidence suggests that
ICAD can also contribute to the development of cogni-
tive impairment and Alzheimer disease although more
studies are needed to establish this association [2-5].
Even so, it is a relative neglected frontier [1]. Despite
the extended use of non invasive diagnostic techniques
as transcranial Doppler (TCD), transcranial color-coded-
duplex (TCCD), magnetic resonance angiography
(MRA) or computed tomography angiography ICAD is
an infradiagnosed and understudied disease when com-
pared to extracranial atherosclerosis.
When it turns to symptomatic, intracranial atherosclero-
sis is a dynamic and aggressive disease. The rate of stroke
recurrence is high (up to 18% in >70% stenosis) despite
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matic intracranial atherosclerosis still remains unknown
[11]. In this context, there is a need to increase our knowl-
edge about basic mechanisms and dynamics of intracranial
atherosclerosis progression from its preclinical stage.
Intracranial atherosclerosis is not an isolated disease,
but related to generalized atherosclerosis affecting other
territories as carotid, coronary or peripheral artery dis-
ease [12,13]. One essential aim in primary prevention is
to find tools to improve the evaluation of “the vulnerable
patient” [14,15]. Classic vascular risk functions (as Fra-
mingham) are now being combined with new markers as
carotid intima-media thickness, ankle-arm index or CRP
values [16] to assess individual vascular risk. Therefore,
the identification of new blood, genetic or instrumental
biomarkers for asymptomatic atherosclerosis may be cru-
cial to predict and prevent future ischemic events.
Traditional approaches have attempted to target ICAD
when it is already symptomatic so there is a lack of studies
in the asymptomatic stage. Population studies aimed to
determine its prevalence and related vascular risk factors
have only been developed in Asian populations, using
transcranial Doppler to assess the presence of stenosis
[17-20]. Therefore, the prevalence of asymptomatic intra-
cranial atherosclerosis remains unknown in Caucasians.
In this context of uncertainty regarding the prevalence
and clinical importance of asymptomatic intracranial
atherosclerosis in Caucasians, we designed a prospective
study called Barcelona-ASIA (ASymptomatic Intracra-
nial Atherosclerosis), aimed (1) to determine the preva-
lence of asymptomatic intracranial atherosclerosis in a
randomly selected Caucasian population with moderate-
high vascular risk; (2) to study its prognostic impact on
the risk of suffering future major ischemic events and/or
cognitive decline; and (3) to identify predictors of the
development, progression and clinical expression of this
condition.
This article describes the protocol details of the Barce-
lona-ASIA study.
Methods/Design
This is a population-based, prospective, long-term fol-
low-up observational study that will include over a thou-
sand randomly selected healthy subjects exposed to
vascular risk factors and without history of stroke or
ischemic heart disease. The study will have two phases,
cross-sectional and longitudinal. In the first cross-
sectional phase, all study subjects will undergo an exten-
sive clinical, laboratory, ultrasound, neuropsychological
and neuroimaging protocol in order to determine the
prevalence of asymptomatic intracranial atherostenoses
among the study population and to identify clinical, bio-
logical and genetic associated factors. In the second
phase, a long-term clinical and TCCD follow-up will be
performed with the purpose of determining the impact of
asymptomatic intracranial atherosclerosis on the inci-
dence of major vascular events and cognitive impairment.
Subject selection
This study will be carried out in the Germans Trias i
Pujol University Hospital, a public health tertiary centre
of the Barcelonès Nord and Maresme region (Catalonia,
Spain), and it is coordinated with the regional Primary
Health Care network. The protocol has been approved
by the Ethics Committee of our institution.
A rural and urban population of approximately
600.000 residents integrates our metropolitan area. This
entire population is registered in a database of the
Primary Care Information Technology System (SIAP).
A sample of 3010 subjects older than 50 years was
randomly selected in 2007 within the PERART study, an
ongoing trial that aims to estimate the prevalence and
prognosis impact of the peripheral artery disease in our
population. Selection of the PERART cohort is described
in detail elsewhere [21]. Framingham and REGICOR
(Framingham calibrated for Spanish population [22])
functions were previously calculated in all these partici-
pants at the initial visit of PERART study.
The ASIA cohort derives from this PERART cohort.
From the initial PERART sample of 3010 subjects, we will
evaluate the 1503 subjects who met the following inclusion
criteria: (1) No history of stroke or transient ischemic
attack; (2) No history of coronary disease; (3) Exposure to
a light-moderate-high vascular risk, assessed by a REGI-
COR≥5 (which is equivalent to a Framingham > 10);
(4) Absence of institutionalization, severe disability or
previous chronic neurological/psychiatric disease.
First, on February 2007 a letter was sent to all 1503
selected participants warning them about the study and
the chance of being called to take part in it. They were
given a 15-day period to express their refusal to collabo-
rate in the study, but no patient denied participation at
that time. Subsequently, all possible participants will be
contacted by phone (up to five calls) during the recruit-
ment phase. A subset of this initial sample may reject to
take part in the study when being informed about the con-
ditions of the study during this phone call. Finally, among
the subjects who will accept to come to our hospital for
the baseline visit, some will be excluded after reassessment
of inclusion criteria (Figure 1). We estimate that about
1000 subjects may complete the study, assuming a 10% of
exclusions and a 20% of not-accepting participants.
Baseline procedures at initial visit in our centre (Figure 2)
1. Signing of informed written consent
2. Clinical data collection. Clinical data of every
subject will be collected in a questionnaire specifi-
cally designed for this study:
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Page 2 of 9◦ Sociodemographic variables: age, sex, socioeco-
nomic status (monthly income in the family
unit), education status (years of schooling,
grade), employment (active, unemployed, retired,
disqualified, housewife).
◦ Vascular risk factors: smoking habit (never,
current, former), alcohol intake (g/day), physical
activity level (sedentary, home-activity, outdoor
activity and grade, walked Km/day in the last
week), personal and family history of hyperten-
sion, diabetes mellitus and dyslipidemia.
◦ Current drug intake (platelet inhibitors, antic-
oagulants, lipid-lowering drugs, antihypertensives,
hypoglycemic agents, antideppresants, etc).
◦ Vascular events presented between inclusion in
the PERART study and baseline visit at our centre
will be recorded: angina, myocardial infarction,
intermittent claudication. Incidental stroke before
the ASIA baseline visit was an exclusion criteria.
◦ Anthropometric variables: height, weight, waist
circumference, current systolic/diastolic blood
pressure values in both arms
◦ Ankle-arm index (AAI) was measured in all
participants in PERART study as previously
described (25).
◦ Others: Personal history of anxiety or depres-
sion, pharmacologic treatments in the moment
of inclusion.
3. Biological and genetic studies.T w e l v es e r u m ,2
citrated plasma, 2 plasma-EDTA and 2 total blood
cryotubes will be collected, processed and stored in
each subject at baseline visit after a minimum of 12
fasting hours. After centrifugation at 3500 rpm and
4°C for 15 minutes, serum or plasma will be blind
coded and stored at -80°C until analyzed.
4. Ultrasound protocol. All the Duplex studies will
be performed in the same ultrasound lab (Neu-
roscience Department of Germans Trias i Pujol Hos-
pital) using a General Electrid Vivid/Pro (GE
Vingamed Ultrasound, Horten, Norway), by two
experienced neurologists. First, a cervical study will
be performed to detect presence and severity of
atherosclerotic plaques in carotid arteries and origin
of vertebral arteries, and to measure the intima-
media thickness (IMT). Later, a transcranial duplex
will be set to examine bilateral intracranial carotid
artery (ICA), middle cerebral artery (MCA), anterior
cerebral artery (ACA), posterior cerebral artery
(PCA), vertebral artery (VA) and basilar artery (BA).
All studies will be performed with subject in supine
position.
a. Extracraneal study: It will be performed using
a linear transducer 5-15 Hz (predefined para-
meters: 8.5 MHz, 4 cm focus, FPS 63.8).
◦ Carotid assessment: First, a high resolution
B-mode study will be conducted in longitudinal
Figure 1 ASIA study sample selection. The diagram shows the sample selection in ASIA study from the reference population. SIAP system:
Primary Care Information Technology System; sbj: subjects; AAI: ankle-arm index; CD: coronary disease.
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Page 3 of 9and cross-sectional planes over the whole visible
length of the following arterial segments: proxi-
mal and distal common carotid artery, carotid
bifurcation and internal carotid artery. The most
pathologic areas in every arterial segment will be
analyzed and images stored.
▪ Atherosclerotic plaques. According to
Manheim consensus criteria, atherosclerotic
plaques are defined as follows: focal structure
encroaching into the arterial lumen of at
least 0.5 mm or 50% of the surrounding IMT
value, or demonstrating a thickness > 1.5 mm
as measured from the media-adventitia inter-
face to the intima-lumen interface [23].
Atherosclerotic plaques will be further char-
acterized by the following criteria:
￿ Plaque surface: regular smooth, irregular,
ulcerated [24]
￿ Echogenicity: anechogenic, hypo-anechogenic,
hypo-isoechogenic, iso-hyperechogenic.
▪ IMT. According to Manheim consensus
criteria, IMT is defined as a double-line pat-
tern (the interface between lumen-intima and
interface between media-adventitia) visualized
by B-mode sonography on both walls of the
carotid arteries in a longitudinal image. IMT
will be measured in regions without athero-
sclerotic plaque, preferably in CCA, in the far
w a l la n dm o r et h a n1 0m ma w a yf r o mc a r o -
tid bifurcation. Two values will be obtained:
manual measurement of maximum IMT and
automated measurement of mean IMT.
Next, Doppler spectrum analyses will be per-
formed to assess the grade of stenosis depending
on the systolic peak velocity [25]: <50%: <125
cm/s; 50-70%: 125-230 cm/s; >70%: > 230 cm/s.
BASELINE VISIT
CLINICAL AND 
ANTHROPOMETRIC DATA 
COLLECTION 
EXTRA AND 
INTRACRANIAL 
DUPLEX ULTRASOUND 
STUDY
BLOOD SAMPLES 
COLLECTION: 
BIOBANK
NEUROPSYCHOLOGICAL 
ASSESMENT
FOLLOW-UP
(5 years)
INCIDENT VASCULAR 
EVENTS AND VASCULAR 
DEATH
SUBJECTS WITH 
ASIA
MRA 
CONFIRMATION
SUBJECTS 
WITHOUT ASIA
FOLLOW-UP IN OUR CENTRE FOLLOW-UP IN PERART STUDY
2 YEAR: DUPLEX AND 
NPS REASSESMENT
Figure 2 ASIA study flow chart. The diagram shows baseline procedures and follow-up in ASIA study. Subjects with asymptomatic intracranial
atherostenoses (ASIA) in basal ultrasound study will undergo a Magnetic Resonance Angiograph (MRA) and will be followed annually in our
centre. Two years after inclusion a new duplex and NPS (neuropsychological) study will be performed. Subjects without ASIA will be followed in
PERART study.
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ered when the stenosis is ≥ 50%. In stenosis <
50% the percentage of luminal obstruction in
axial plane will be calculated.
◦ Vertebral arteries: Extracranial vertebral
arteries will be studied in the following segments:
V2 segment (longitudinal insonation plane,
framed by acoustical shadow of transverse pro-
cesses); V0/V1 segment (origin from subclavian
artery); and V3 segment (transverse insonation
below mastoid bone, comma-shaped). We will
characterize vertebral arteries following spectrum
analyses [26] as normal, stenosis >50% (SP >125
cm/s) or occlusion (absence of telediastolic flow).
b. Transcranial color-coded-duplex (TCCD)
study: It will be performed using a 1.6-3.2 MHz
transducer via transtemporal and transforaminal
windows (patient in supine position) to evaluate
circle of Willis and its branches, following con-
sensus recommendations for an optimal explora-
tion [27]. Each large cerebral artery will be
investigated by spectral Doppler sonography with
the color-coded Doppler signal used as a “road
map”. Flow direction, peak systolic (PSV), mean
flow (MFV) and end-diastolic (PDV) velocities,
pulsatility index (PI) and resistance index (RI)
will be noted for every insonated artery. Angle
correction will be performed when the Doppler
sample volume is located within a straight vessel
segment of at least 15-20 mm. By transtemporal
bone window, we will study intracranial carotid
artery (ICA) in axial and coronal planes, middle
cerebral artery (M1 and M2 segments), anterior
cerebral artery (A1 segment) and posterior cere-
bral artery (P1 and P2 segments). By transforam-
inal bone window we will study vertebral artery
(V4 segment) and basilar artery (BA). If there is
an insufficient acoustic window in transcranial
examination, an enhance contrast agent will be
used intravenously (Sonovue
®)
Intracranial stenosis definition and grading
An intracranial stenosis will be diagnosed following pre-
vious published criteria. First, using color-coded mode
as a road map we will assess flow direction and presence
of segmental color aliasing phenomena in all arteries.
Then, we will determine the presence of an intracranial
stenosis if the spectral analysis shows a focal increase of
PSV and/or PDV higher than the mean value + 2 SD
for the corresponding cerebral artery or low-frequency,
high-intensity Doppler signals, spectral widening or
musical murmurs [28]. An example of intracranial ste-
nosis is illustrated in figure 3. ICA stenosis will be diag-
nosed following published reference velocity values and
recommendations, assessing not only differences in velo-
cities between the two sides but also looking for activa-
tion of collaterals (anterior and/or posterior
communicating arteries) and/or flow repercussion in
extracranial internal carotid [29-31]. Following systolic
peak criteria MCA stenosis will be graded into low-
grade (140-209 cm/s), moderate (210-279 cm/s) and
high-grade (>280 cm/s) [32]. For the rest of intracranial
arteries we will follow cut-off values of PSV for < 50%
and ≥ 50% stenosis [33]: ≥120/≥155 cm/s for anterior
cerebral artery; ≥100/≥145 cm/s for posterior cerebral
A B
C
Figure 3 Example of right middle cerebral artery (MCA) stenosis. In left image (A) TCCD color mode shows an area of narrowing and color
aliasing in the proximal segment of right MCA (arrow). In the right image (B), an spectral flow analyses is set to determine systolic peak velocity
and appearance of low-frequency, high-intensity Doppler signals. In the middle superimposed image (C), a magnetic resonance angiogram
(MRA) made in the same subject shows a flow gap in right MCA (circle) corresponding to a high-grade stenosis.
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artery. Furthermore, when a focal increase of velocity is
detected, the proximal and distal vessel segments will be
evaluated (pre-stenotic and post-stenotic flow patterns
in the upstream and downstream vessel segments) and
p o t e n t i a lc o l l a t e r a lp a t h w a y sw i l lb ec o n s i d e r e di no r d e r
to assess hemodynamic repercussion. Number, location
and severity of intracranial stenosis will be recorded in
every subject.
Neuropsychological assessment
Neuropsychological studies will be performed at baseline
visit in our centre after accepting and signing specific
informed written consent. Neuropsychological studies
will be performed by neuropsychologists blinded to neu-
rosonology study results. General cognitive status will
be measured using the Mini Mental State Examination.
Depressive symptoms will be assessed with the Geriatric
Depression Scale with scores higher than 5 being indica-
tive of probable depression. Cognitive measures will
assess executive functions, attention, verbal and visual
memory, visuoconstructive abilities, speed/visuomotor
coordination and language.
Magnetic Resonance (MR) and MR-angiography (MRA)
study
A complete MR will be conducted to patients with stenosis
detected by TCCD if they have no contraindication. All
explorations will be performed with the same 1.5T MR
(Intera, Philips), with an echo-planar capacity of 25 m
Teslas/m and time-rises of 300-350 microseconds. The
MRA will be performed by a time-of-flight (TOF) sequence,
using 1.5 mm section slides, 200-mm field of view, 200 ×
512 matrix, and 7-11 minutes of acquisition. Maximal
intensity projection (MIP) reconstructions will be set.
All MR studies will be performed in a 6 months maxi-
mum period from baseline inclusion visit (sonographic
study). MRAs will be analyzed by a neuroradiologist
blind to clinical and sonographic data. Intracranial ste-
nosis will be defined as flow irregularity and focal nar-
rowing >50% in luminal reduction affecting the main
cerebral arteries.
Primary prevention strategies
- Vascular risk factors control (obesity, hyperten-
sion, dyslipidemia, hyperglycemia, sedentarism,
smoking habit...). The family doctor will assume
their control, after receiving a brief report of the
neurosonolgical study and the clinical data obtained
in the baseline visit in our centre.
- Antiplatelet treatment: After neurosonological
study, antithrombotic treatment (300 mg of aspirin
or 75 mg of clopidogrel-if there is intolerance/allergy
to aspirin-) will be recommended according to
AHA/ASA primary prevention guidelines [34] in the
following cases: asymptomatic carotid stenosis >50%;
significant stenosis of extracranial vertebral arteries
and/or asymptomatic intracranial stenosis.
- Carotid revascularization: Following the Asymp-
tomatic Carotid Atherosclerosis Study (ACAS) [35],
carotid revascularization (endarterectomy or endo-
vascular) will be recommended in carotid stenosis
>60%, performed by surgeons or interventional neu-
roradiologists with periprocedural complication rates
lower than 3%.
ASIA clinical and image database
Clinical data will be recorded in CRFs. Blood samples
will be processed, frozen and stored in our biobank.
Images obtained in neurosonological studies will be
stored in a specific workstation (Echo Pack) to be ana-
lyzed afterwards. A prospective electronic database will
be created with clinical, neurosonological and laboratory
variables of the cross-over and longitudinal phases of
the study.
Prospective follow-up (cohort study)
Participants will be followed-up annually for 5 years by
primary care physicians of the PERART study to docu-
ment the incidence of vascular events, therapeutic com-
pliance and control of vascular risk factors. The primary
endpoint will be the combined incidence of any major
vascular event: acute myocardial infarction or angina
requiring hospitalization, ischemic stroke, hemorrhagic
stroke and vascular death.
Subjects with intracranial stenosis at baseline will be
controlled in the Germans Trias i Pujol University Hos-
pital annually. A new neurosonological and neuropsy-
chological study will be performed two years after
inclusion to study progression or regression of the intra-
cranial lesions and cognitive decline. In addition, a
matched group of subjects without baseline ASIA will
be studied. Vascular events will be adjudicated by an
external monitoring committee comprising of two neu-
rologists and one cardiologist.
Satatistical considerations
Statistics will be performed with the SPSS 18.0 statistical
package. Quantitative variables will be compared with
the Student’s t test and analysis of variance will be per-
formed, using the corresponding non parametric tests
when necessary. Chi squared test will be used for com-
parisions of categorical variables. In the cross-over
phase, multiple logistic regression models will be per-
formed to identify variables independently associated
with the presence of asymptomatic intracranial atheros-
tenoses. In longitudinal phase, survival analysis for the
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cular event will be performed with the Kaplan-Meier
curves according to the presence/absence of intracranial
stenosis. Cox multivariate regression models will be
used to compare the probability of having a vascular
event in the follow up cohorts, adjusting for the neces-
sary covariates. The relative risk (hazards ratios) will be
given whit their corresponding 95% confidence intervals.
Discussion
Despite of its relevant impact on public health and the
development of new non-invasive diagnostic tests, intra-
cranial atherosclerosis is still an understudied pathology.
ICAD is the origin of 5-10% of strokes in Caucasians
[36,37] and up to 50% in Asians [38,39]. Limited data
about preclinical stage and natural history of ICAD are
available in the general population. The only population
studies to determine its prevalence in stroke-free indivi-
duals were developed in Asians without prospective fol-
low-up to assess the risk of vascular events (21-25).
These studies have some limitations as they evaluated
intracranial stenosis only with transcranial Doppler, they
did not use contrast agents and some of them only eval-
uated middle cerebral artery. There is too much variabil-
ity in their methods to compare them and to establish a
real prevalence. Our study is the first to evaluate the
prevalence of asymptomatic intracranial atherosclerosis
in Caucasians. As it is a cohort study we will also inves-
tigate the ASIA prognosis impact, not only in the
appearance of cerebral events but also in coronary and
peripheral artery disease, and in the development of vas-
cular cognitive impairment.
We will determine clinical, instrumental (IMT and
AAI measurements) and biological risk factors related to
asymptomatic ICAD in order to identify factors asso-
ciated with its progression and clinical expression. We
will be able to analyze whether factors that have been
already related to disease progression in its symptomatic
stage, such as inflammatory markers, also pay a role in
asymptomatic intracranial atherosclerosis [40-43].
Furthermore, we would evaluate the importance of
using those risk factors as risk markers in terms of gen-
eral vascular primary prevention.
The reasons that explain the racial and interindividual
differences observed in the distribution of cerebral
atherosclerosis affecting extra and intracranial arteries
remain poorly understood. Differences in vascular risk
factors profile, inflammatory markers, life-style and
genetic susceptibility are proposed as possible answers
but studies are contradictory. Our study could contri-
bute to clarify this matter since we will evaluate extra-
cranial and intracranial vasculature in each patient.
Finally, many studies are stressing the possible rela-
tionship between ICAD and cognitive impairment.
A simultaneous protocol in collaboration with our
neuropsychological team has been created to evaluate
cognitive status in every subject of ASIA study. Conse-
quently, the ASIA results may help to find out biologi-
cal, sonographic and clinical factors related to the
presence of vascular cognitive impairment in asympto-
matic individuals.
Strengths of this study are: 1). Randomized, large sam-
ple population study that will provide a generalized esti-
mation of prevalence of asymptomatic intracranial
stenosis in Caucasians, which nowadays remains
unknown; 2). TCCD assessment of all intracranial
arteries (anterior and posterior circulation) in all sub-
jects, use of contrast agents if insufficient acoustic win-
dow and MRA assessment in subjects with stenosis; 3).
Complete cerebral neurosonology study in each patient
(intracranial and extracranial) because an adequate
interpretation of intracranial findings always requires a
careful assessment of the influence of extracranial
pathology on the intracranial hemodynamics; 4). A bio-
bank will be created allowing investigation of molecular
and genetic factors related to the presence and progres-
sion of intracranial atherosclerosis; 5). Long-term fol-
low-up that will allow us to establish prognosis and
related factors of incidental stroke and major vascular
events, and to evaluate progression/regression of intra-
cranial lesions.
We hope ASIA study will contribute to the better
understanding of intracranial atherosclerotic disease
dynamics and help us to identify new potential thera-
peutic and prevention targets for this condition.
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